Phenotypes associated with this allele

• Allele Symbol: Tg(Mx1-cre)29-4Her
• Allele Name: transgene insertion 29-4, Joachim Herz
• Allele ID: MGI:2180899
• Summary: 14 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Hgf^tm1Jmw/Hgf^tm1Jmw Tg(Mx1-cre)29-4Her/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL	MGI:3716971
cn2	Insig1^tm1Mbjg/Insig1^tm1Mbjg Insig2^tm1Mbjg/Insig2^tm1Mbjg Tg(Mx1-cre)29-4Her/0	involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * SJL	MGI:3607700
cn3	Insig1^tm1Mbjg/Insig1^tm1Mbjg Tg(Mx1-cre)29-4Her/0	involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * SJL	MGI:3607696
cn4	Mbtps1^tm1Jdh/Mbtps1^tm1Jdh Tg(Mx1-cre)29-4Her/0	involves: 129S6/SvEvTac * C57BL/6J * SJL	MGI:3846193
cn5	Scap^tm1Mbjg/Scap^tm1Mbjg Tg(Mx1-cre)29-4Her/0	involves: 129S6/SvEvTac * C57BL/6J * SJL	MGI:3801617
cn6	Apoe^tm1Lmh/Apoe^tm1Lmh Ldlr^tm1Her/Ldlr^tm1Her Lrp1^tm2Her/Lrp1^tm2Her Tg(Mx1-cre)29-4Her/0	involves: 129S7/SvEvBrd * C57BL/6J * SJL	MGI:3797226
cn7	Lrp1^tm2Her/Lrp1^tm2Her Tg(Mx1-cre)29-4Her/0	involves: 129S7/SvEvBrd * C57BL/6J * SJL	MGI:2180900
cn8	Ldlr^tm1Her/Ldlr^tm1Her Lrp1^tm2Her/Lrp1^tm2Her Tg(Mx1-cre)29-4Her/0	involves: 129S7/SvEvBrd * C57BL/6J * SJL	MGI:4943553
cn9	Ldlr^tm1Her/Ldlr^tm1Her Lrp1^tm2Her/Lrp1^tm2Her Vldlr^tm1Her/Vldlr^tm1Her Tg(Mx1-cre)29-4Her/0	involves: 129S7/SvEvBrd * C57BL/6 * SJL	MGI:3797223
cn10	Lrp1^tm2Her/Lrp1^tm2Her Tg(Mx1-cre)29-4Her/0	involves: 129S7/SvEvBrd * C57BL/6 * SJL	MGI:3797224
cn11	Ldlr^tm1Her/Ldlr^tm1Her Lrp1^tm2Her/Lrp1^tm2Her Tg(Mx1-cre)29-4Her/0	involves: 129S7/SvEvBrd * C57BL/6 * SJL	MGI:3797225
cx12	Apoe^tm1Khw/Apoe^tm1Khw Tg(Mx1-cre)29-4Her/0	B6.Cg-Apoe^tm1Khw Tg(Mx1-cre)29-4Her	MGI:5499989
cx13	Apoe^tm1Rraf/Apoe^tm1Rraf Tg(Mx1-cre)29-4Her/0	B6.Cg-Apoe^tm1Rraf Tg(Mx1-cre)29-4Her	MGI:5499988
cx14	Apoe^tm1Khw/Apoe^tm1Khw Tg(Mx1-cre)29-4Her/?	involves: 129S4/SvJae * C57BL/6 * SJL	MGI:3818180

Genotype
MGI:3716971

cn1

• Allelic Composition: Hgf^tm1Jmw/Hgf^tm1Jmw; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

liver/biliary system

decreased hepatocyte proliferation ( J:97145 )

• liver regenerative capacity (assessed by BrdU incorporation) is decreased 1.5-fold following pI:pC treatment and CCl₄ administration, compared to controls receiving PBS and CCl₄ treatment

impaired liver regeneration ( J:97145 )

• 6-8 week old mice treated with poly I:C to induce cre expression, treated with CCl₄ to induce liver injury show decreased liver regenerative capacity (~1.5-fold decrease)

cellular

decreased hepatocyte proliferation ( J:97145 )

• liver regenerative capacity (assessed by BrdU incorporation) is decreased 1.5-fold following pI:pC treatment and CCl₄ administration, compared to controls receiving PBS and CCl₄ treatment

Genotype
MGI:3607700

cn2

• Allelic Composition: Insig1^tm1Mbjg/Insig1^tm1Mbjg; Insig2^tm1Mbjg/Insig2^tm1Mbjg; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * SJL

homeostasis/metabolism

abnormal lipid homeostasis ( J:101203 )

• hepatic sterol synthesis is elevated 5-fold and does not decline with a high-cholesterol diet as in controls

decreased circulating triglyceride level ( J:101203 )

• triglycerides are slightly reduced when fed a chow diet ad libitum

abnormal cholesterol homeostasis ( J:101203 )

• hepatic HMG-CoA reductase activity is elevated and fails to decline after cholesterol feeding as in controls

increased circulating cholesterol level ( J:101203 )

• plasma cholesterol is slightly elevated when fed a chow diet ad libitum

increased liver cholesterol level ( J:101203 )

• hepatic content of total cholesterol is increased by 4-fold, however it does not increase further with cholesterol feeding

• hepatic content of free cholesterol is increased by 1.4-fold and the cholesteryl ester content by 15-fold

increased fatty acids level ( J:101203 )

• hepatic fatty acid synthesis is 3-fold higher when fed the low-cholesterol diet

increased liver triglyceride level ( J:101203 )

• hepatic content of total triglycerides is increased by 6-fold

liver/biliary system

abnormal liver morphology ( J:101203 )

• accumulation of lipids in the liver

increased liver cholesterol level ( J:101203 )

• hepatic content of total cholesterol is increased by 4-fold, however it does not increase further with cholesterol feeding

• hepatic content of free cholesterol is increased by 1.4-fold and the cholesteryl ester content by 15-fold

increased liver triglyceride level ( J:101203 )

• hepatic content of total triglycerides is increased by 6-fold

pale liver ( J:101203 )

• liver Is pale due to accumulation of lipids

abnormal hepatobiliary system physiology ( J:101203 )

• hepatic sterol and fatty acid synthesis is elevated and hepatic triglyceride and cholesterol content is increased

Genotype
MGI:3607696

cn3

• Allelic Composition: Insig1^tm1Mbjg/Insig1^tm1Mbjg; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * SJL

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:101203 )

N • plasma cholesterol, triglycerides, insulin, glucose, and free fatty acids levels, and hepatic cholesterol and triglyceride levels are normal

Genotype
MGI:3846193

cn4

• Allelic Composition: Mbtps1^tm1Jdh/Mbtps1^tm1Jdh; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * SJL

homeostasis/metabolism

abnormal lipid homeostasis ( J:72930 )

• following administration of pIpC, lipid synthesis is decrease compared to in similarly treated wild-type mice

abnormal intestinal lipid absorption ( J:72930 )

• following administration of pIpC, lipid clearance from the plasma is decreased compared to in similarly treated wild-type mice

decreased circulating cholesterol level ( J:72930 )

• decreased 36% following administration of pIpC

decreased circulating triglyceride level ( J:72930 )

• decreased 50% following administration of pIpC

decreased liver triglyceride level ( J:72930 )

• following administration of pIpC

digestive/alimentary system

abnormal intestinal lipid absorption ( J:72930 )

• following administration of pIpC, lipid clearance from the plasma is decreased compared to in similarly treated wild-type mice

liver/biliary system

decreased liver triglyceride level ( J:72930 )

• following administration of pIpC

Genotype
MGI:3801617

cn5

• Allelic Composition: Scap^tm1Mbjg/Scap^tm1Mbjg; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * SJL

homeostasis/metabolism

abnormal lipid homeostasis ( J:69592 )

• following induction with pIpC, fatty acid synthesis is decreased 84% in the liver

decreased circulating free fatty acids level ( J:69592 )

• following induction with pIpC

abnormal cholesterol homeostasis ( J:69592 )

• following induction with pIpC, cholesterol synthesis is decreased 71% in the liver

decreased liver cholesterol level ( J:69592 )

• following induction with pIpC

decreased liver triglyceride level ( J:69592 )

• following induction with pIpC

liver/biliary system

decreased liver cholesterol level ( J:69592 )

• following induction with pIpC

decreased liver triglyceride level ( J:69592 )

• following induction with pIpC

Genotype
MGI:3797226

cn6

• Allelic Composition: Apoe^tm1Lmh/Apoe^tm1Lmh; Ldlr^tm1Her/Ldlr^tm1Her; Lrp1^tm2Her/Lrp1^tm2Her; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6J * SJL

homeostasis/metabolism

decreased circulating cholesterol level ( J:90547 )

• following pIpC treatment, plasma cholesterol level is lower compared to mutant mice wild-type for Lrp1

decreased circulating LDL cholesterol level ( J:90547 )

• following pIpC treatment, plasma LDL cholesterol level is lower compared to mutant mice wild-type for Lrp1

decreased circulating VLDL cholesterol level ( J:90547 )

• following pIpC treatment, plasma VLDL cholesterol level is lower compared to mutant mice wild-type for Lrp1

increased circulating cholesterol level ( J:117317 )

increased circulating HDL cholesterol level ( J:117317 )

increased circulating LDL cholesterol level ( J:117317 )

decreased circulating triglyceride level ( J:90547 )

• following pIpC treatment, plasma triglyceride level is lower compared to mutant mice wild-type for Lrp1

increased circulating triglyceride level ( J:117317 )

abnormal circulating protein level ( J:90547 )

• increase in tissue type plasminogen activator levels by 4 weeks after pIpC treatment

abnormal circulating enzyme level ( J:90547 )

• following pIpC treatment, plasma lipoprotein lipase level is higher compared to mutant mice wild-type for Lrp1

• however, no increase in lipoprotein lipase activity is detected

increased circulating factor VIII level ( J:90547 , J:117317 )

• increase in Factor VIII levels by 4 weeks after pIpC treatment (J:90547)

• mice show elevated FVIII (Factor 8) levels (J:117317)

increased circulating von Willebrand factor level ( J:90547 )

• increase in von Willebrand factor levels by 4 weeks after pIpC treatment

cardiovascular system

increased susceptibility to atherosclerosis ( J:90547 )

• increase in lesion size in pIpC treated mice compared to untreated controls

• however, no change in lesion composition is detected

Genotype
MGI:2180900

cn7

• Allelic Composition: Lrp1^tm2Her/Lrp1^tm2Her; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6J * SJL

homeostasis/metabolism

abnormal blood homeostasis ( J:83443 )

• clearance of Factor VII from the plasma is slower in pIpC treated mice

increased circulating factor VIII level ( J:83443 )

• increase in Factor VIII levels by 10 days after pIpC treatment

• increase in levels persists for at least 6 weeks after pIpC treatment

• the ratio of Factor VIII to von Willebrand factor is also increased following pIpC treatment

increased circulating von Willebrand factor level ( J:83443 )

• increase in von Willebrand factor levels by 10 days after pIpC treatment

• increase in levels persists for at least 6 weeks after pIpC treatment

liver/biliary system

abnormal liver physiology ( J:83443 )

• clearance of Factor VII from the plasma is slower in pIpC treated mice

Genotype
MGI:4943553

cn8

• Allelic Composition: Ldlr^tm1Her/Ldlr^tm1Her; Lrp1^tm2Her/Lrp1^tm2Her; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6J * SJL

homeostasis/metabolism

increased circulating cholesterol level ( J:67929 )

• increase in total plasma cholesterol levels within 10 days of pIpC injection

increased circulating LDL cholesterol level ( J:67929 )

• large increase of plasma lipoproteins in the LDL size range within 10 days of pIpC injection

increased circulating VLDL cholesterol level ( J:67929 )

• large increase of plasma lipoproteins in the chylomicron remnant/VLDL size range within 10 days of pIpC injection

increased circulating triglyceride level ( J:67929 )

• within 10 days of pIpC injection

abnormal circulating apolipoprotein level ( J:67929 )

• within 10 days of pIpC injection, concentrations of apoB48 are dramatically increased

• this increase is primarily responsible for the increase in plasma cholesterol and triglyceride levels

Genotype
MGI:3797223

cn9

• Allelic Composition: Ldlr^tm1Her/Ldlr^tm1Her; Lrp1^tm2Her/Lrp1^tm2Her; Vldlr^tm1Her/Vldlr^tm1Her; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * SJL

homeostasis/metabolism

increased circulating factor VIII level ( J:117317 )

• mice show significantly elevated FVIII (Factor 8), similar to Ldlr/Lrp double mutants

Genotype
MGI:3797224

cn10

• Allelic Composition: Lrp1^tm2Her/Lrp1^tm2Her; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * SJL

homeostasis/metabolism

abnormal circulating protein level ( J:117317 )

• tissue plasminogen activator (t-PA) levels are increased by 2.4-fold relative to controls

increased circulating factor VIII level ( J:117317 )

• FVIII levels are slightly elevated by 1.6-fold relative to controls

increased circulating von Willebrand factor level ( J:117317 )

• von Willebrand factor levels are sligthly elevated by 1.3-fold relative to controls

Genotype
MGI:3797225

cn11

• Allelic Composition: Ldlr^tm1Her/Ldlr^tm1Her; Lrp1^tm2Her/Lrp1^tm2Her; Tg(Mx1-cre)29-4Her/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * SJL

homeostasis/metabolism

increased circulating cholesterol level ( J:117317 )

• cholesterol levels are significantly increased (>10-fold) compared to controls

increased circulating triglyceride level ( J:117317 )

• triglyceride levels are significantly increased (>10-fold) compared to controls

increased circulating factor VIII level ( J:117317 )

• FVIII levels are increased by 4.2-fold compared to controls

increased circulating von Willebrand factor level ( J:117317 )

• von Willebrand factor levels are increased by 3.3-fold compared to controls

Genotype
MGI:5499989

cx12

• Allelic Composition: Apoe^tm1Khw/Apoe^tm1Khw; Tg(Mx1-cre)29-4Her/0
• Genetic Background: B6.Cg-Apoe^tm1Khw Tg(Mx1-cre)29-4Her

homeostasis/metabolism

abnormal circulating lipid level ( J:196923 )

• mice fed a high cholesterol diet exhibit increased in all lipid classes, phospholipid, free cholesterol, cholesterol esters and triglycerides in the VLDL fractions compared with Apoe^tm1Rraf homozygotes fed a high cholesterol diet

increased circulating cholesterol level ( J:196923 )

• at least 2-fold in mice fed a high cholesterol diet

• modest increase in female, but not male, mice fed a high cholesterol diet at 4 and 12 weeks compared with Apoe^tm1Rraf homozygotes fed a high cholesterol diet

increased circulating VLDL cholesterol level ( J:196923 )

• in mice fed a high cholesterol diet compared with Apoe^tm1Rraf homozygotes fed a high cholesterol diet

hyperlipidemia ( J:196923 )

• female mice fed a high cholesterol diet develop hypercholesterolemia faster than male mice

abnormal apolipoprotein level ( J:196923 )

• macrophages release reduced ApoE compared with macrophages from Apoe^tm1Rraf homozygotes

cardiovascular system

increased susceptibility to atherosclerosis ( J:196923 )

• in the descending aorta of mice fed a high cholesterol diet compared with Apoe^tm1Rraf homozygotes fed a high cholesterol diet

• however, lesion formation in the aortic arch is equivalent

immune system

immune system phenotype ( J:196923 )

N • leukocyte levels are not altered

Genotype
MGI:5499988

cx13

• Allelic Composition: Apoe^tm1Rraf/Apoe^tm1Rraf; Tg(Mx1-cre)29-4Her/0
• Genetic Background: B6.Cg-Apoe^tm1Rraf Tg(Mx1-cre)29-4Her

homeostasis/metabolism

abnormal circulating cholesterol level ( J:196923 )

• at 4 and 12 weeks, female mice fed a high cholesterol diet exhibit lower levels compared with Apoe^tm1Khw homozygotes fed a high cholesterol diet

decreased circulating VLDL cholesterol level ( J:196923 )

• in mice fed a high cholesterol diet compared with Apoe^tm1Khw homozygotes fed a high cholesterol diet

increased circulating cholesterol level ( J:196923 )

• at least 2-fold in mice fed a high cholesterol diet

hyperlipidemia ( J:196923 )

• female mice fed a high cholesterol diet develop hypercholesterolemia faster than male mice

abnormal apolipoprotein level ( J:196923 )

• macrophages release increased ApoE compared with macrophages from Apoe^tm1Rraf homozygotes

cardiovascular system

decreased susceptibility to atherosclerosis ( J:196923 )

• in the descending aorta of mice fed a high cholesterol diet compared with Apoe^tm1Khw homozygotes fed a high cholesterol diet

• however, lesion formation in the aortic arch is equivalent

immune system

immune system phenotype ( J:196923 )

N • leukocyte levels are not altered

Genotype
MGI:3818180

cx14

• Allelic Composition: Apoe^tm1Khw/Apoe^tm1Khw; Tg(Mx1-cre)29-4Her/?
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * SJL

homeostasis/metabolism

increased circulating cholesterol level ( J:75681 )

• substantial increase in plasma cholesterol on a high fat diet, reversible after cre induction with pIpC

increased circulating LDL cholesterol level ( J:75681 )

• slight on a normal diet

increased circulating VLDL cholesterol level ( J:75681 )

• slightly on a normal diet

increased circulating triglyceride level ( J:75681 )

• slight increase on a normal diet

• substantial increase on a high fat diet, reversible after cre induction using pIpC